Regulatory News:
GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced it has received an award from the French national research agency, ANR (Agence Nationale de Recherche), for its COVERI project focused on understanding the role of human endogenous retrovirus (HERV) proteins in the abnormal immune-inflammation or the neurological damages suffered by important subsets of COVID-19 patients.
In June 2020, GeNeuro signed a research agreement with the CIRI (International Center for Research in Infectiology), in Lyon, France, a leading research institute against infectious diseases. This research effort concentrates on understanding the viral-host DNA interplay that is known to be able to derepress HERV gene locking mechanisms and produce pathogenic HERV proteins. It is suspected that proteins of the HERV-W family, with known pro-inflammatory and neurodegenerative properties, may be used by SARS-CoV-2 as a Trojan horse, which would bring new light in understanding syndromes associated to COVID-19 as well as a new opportunity to treat some of its worst consequences.
Based on initial results provided to the ANR, GeNeuro was awarded the grant as part of COVID-19 Research Action, which aims to support short-term research work in connection with the pandemic. GeNeuro will receive €137,000 to cover costs in the continuation of the collaborative research project, at and with the CIRI, to analyze a larger number of samples from multicenter cohorts of COVID-19 patients in Europe.
"We are very proud to receive this recognition from ANR and to play our part in the global efforts in combatting the COVID-19 pandemic. Our partnership research with the CIRI leverages GeNeuro's unique knowledge in human endogenous retroviruses, and CIRI's world class expertise in the fight against infection. By doing so, we aim to expand our understanding of COVID-19 immunoinflammatory syndromes and neuronal damage to identify how we can best tackle the disease through this novel pathway," said Dr. Hervé Perron, Chief Scientific Officer of GeNeuro
"This excellent collaboration with GeNeuro is playing an important role in efforts to address COVID-19 by expanding our understanding of the role of human endogenous retroviruses in the disease. Many questions still need to be addressed, such as why does a virus like SARS-CoV-2 provoke the cytokine storm as well as sometimes delayed, neurological damage in a significant subset of patients. Human endogenous retroviruses (HERVs), which are the remnants of past viral infections in our genome, can be activated by exogenous viruses and could be key players in understanding how to stop or prevent superimposed pathogenic effects," said Dr. Branka Horvat, Research Director at the French Institute of Health and Medical Research's International Center for Infectiology Research (CIRI) in Lyon
Should the research result in a proof-of-concept, GeNeuro's temelimab, a monoclonal antibody designed to neutralize the pathogenic envelope protein pHERV-W that has already proven its excellent tolerability in Phase 2 trials, could be made immediately available for a therapeutic intervention against the severe immune and neurological consequences of COVID-19. This would provide a new and complementary approach in the treatment of SARS-CoV-2-infected patients.
About GeNeuro
GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
Twitter YouTube LinkedIn
Disclaimer
This press release contains certain forward looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005873/en/
Contacts:
GeNeuro
Jesús Martin-Garcia
Chairman and CEO
+41 22 552 4800
investors@geneuro.com
NewCap (France)
Louis-Victor Delouvrier Mathilde Bohin (investors)
+33 1 44 71 98 52
Nicolas Merigeau (media)
+33 1 44 71 94 98
geneuro@newcap.eu
Halsin Partners
Mike Sinclair (media)
+44 20 7318 2955
msinclair@halsin.com
LifeSci Advisors
Chris Maggos (investors)
+41 79 367 6254
chris@lifesciadvisors.com